IBDEI2JJ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,42613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42613,1,3,0)
 ;;=3^Disp fx of 4th metsl bone, r ft, subs w/ nonunion
 ;;^UTILITY(U,$J,358.3,42613,1,4,0)
 ;;=4^S92.341K
 ;;^UTILITY(U,$J,358.3,42613,2)
 ;;=^5045190
 ;;^UTILITY(U,$J,358.3,42614,0)
 ;;=S92.001A^^192^2137^209
 ;;^UTILITY(U,$J,358.3,42614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42614,1,3,0)
 ;;=3^Fx of rt calcaneus,init w/ nonunion,unspec
 ;;^UTILITY(U,$J,358.3,42614,1,4,0)
 ;;=4^S92.001A
 ;;^UTILITY(U,$J,358.3,42614,2)
 ;;=^5044353
 ;;^UTILITY(U,$J,358.3,42615,0)
 ;;=S92.314A^^192^2137^287
 ;;^UTILITY(U,$J,358.3,42615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42615,1,3,0)
 ;;=3^Nondisp fx of 1st metrsl bone,rt ft,init w/ nonunion
 ;;^UTILITY(U,$J,358.3,42615,1,4,0)
 ;;=4^S92.314A
 ;;^UTILITY(U,$J,358.3,42615,2)
 ;;=^5045081
 ;;^UTILITY(U,$J,358.3,42616,0)
 ;;=M84.572K^^192^2137^393
 ;;^UTILITY(U,$J,358.3,42616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42616,1,3,0)
 ;;=3^Path fx in neoplst disease,lft ankl,subs w/ nonunion
 ;;^UTILITY(U,$J,358.3,42616,1,4,0)
 ;;=4^M84.572K
 ;;^UTILITY(U,$J,358.3,42616,2)
 ;;=^5014181
 ;;^UTILITY(U,$J,358.3,42617,0)
 ;;=M84.68XA^^192^2137^394
 ;;^UTILITY(U,$J,358.3,42617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42617,1,3,0)
 ;;=3^Path fx initial w/ nonunion,oth disease,oth site
 ;;^UTILITY(U,$J,358.3,42617,1,4,0)
 ;;=4^M84.68XA
 ;;^UTILITY(U,$J,358.3,42617,2)
 ;;=^5134051
 ;;^UTILITY(U,$J,358.3,42618,0)
 ;;=M10.071^^192^2138^14
 ;;^UTILITY(U,$J,358.3,42618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42618,1,3,0)
 ;;=3^Gout,Idiopathic Rt Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42618,1,4,0)
 ;;=4^M10.071
 ;;^UTILITY(U,$J,358.3,42618,2)
 ;;=^5010303
 ;;^UTILITY(U,$J,358.3,42619,0)
 ;;=M10.072^^192^2138^13
 ;;^UTILITY(U,$J,358.3,42619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42619,1,3,0)
 ;;=3^Gout,Idiopathic Lft Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42619,1,4,0)
 ;;=4^M10.072
 ;;^UTILITY(U,$J,358.3,42619,2)
 ;;=^5010304
 ;;^UTILITY(U,$J,358.3,42620,0)
 ;;=M10.272^^192^2138^10
 ;;^UTILITY(U,$J,358.3,42620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42620,1,3,0)
 ;;=3^Gout,Drug-Induced Lft Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42620,1,4,0)
 ;;=4^M10.272
 ;;^UTILITY(U,$J,358.3,42620,2)
 ;;=^5010352
 ;;^UTILITY(U,$J,358.3,42621,0)
 ;;=M10.271^^192^2138^12
 ;;^UTILITY(U,$J,358.3,42621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42621,1,3,0)
 ;;=3^Gout,Drug-Induced Rt Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42621,1,4,0)
 ;;=4^M10.271
 ;;^UTILITY(U,$J,358.3,42621,2)
 ;;=^5010351
 ;;^UTILITY(U,$J,358.3,42622,0)
 ;;=M10.29^^192^2138^11
 ;;^UTILITY(U,$J,358.3,42622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42622,1,3,0)
 ;;=3^Gout,Drug-Induced Multiple Sites
 ;;^UTILITY(U,$J,358.3,42622,1,4,0)
 ;;=4^M10.29
 ;;^UTILITY(U,$J,358.3,42622,2)
 ;;=^5010355
 ;;^UTILITY(U,$J,358.3,42623,0)
 ;;=M10.172^^192^2138^15
 ;;^UTILITY(U,$J,358.3,42623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42623,1,3,0)
 ;;=3^Gout,Lead-Induced Lt Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42623,1,4,0)
 ;;=4^M10.172
 ;;^UTILITY(U,$J,358.3,42623,2)
 ;;=^5010328
 ;;^UTILITY(U,$J,358.3,42624,0)
 ;;=M10.171^^192^2138^16
 ;;^UTILITY(U,$J,358.3,42624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42624,1,3,0)
 ;;=3^Gout,Lead-Induced Rt Ankle/Foot
 ;;^UTILITY(U,$J,358.3,42624,1,4,0)
 ;;=4^M10.171
 ;;^UTILITY(U,$J,358.3,42624,2)
 ;;=^5010327
 ;;^UTILITY(U,$J,358.3,42625,0)
 ;;=L92.3^^192^2138^17
 ;;^UTILITY(U,$J,358.3,42625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42625,1,3,0)
 ;;=3^Granuloma,FB of Skin/Subcutaneous Tissue
